When one day changes the story.

Trial readouts, regulatory decisions, deals and rulings — the events that reprice a stock in a single session. What was disclosed, what was not, and what a shareholder is actually left holding.

1 analysis · 7 linked sources

MRNA
clinical

Moderna doubled on a trial that met its endpoints. The effect size was not disclosed.

INTerpath-001 hit recurrence-free and distant metastasis-free survival — the first positive Phase 3 for an mRNA cancer therapy. The topline said statistically significant and clinically meaningful. It did not say by how much, and roughly $30 billion of market value moved on the difference.

Event
Published
Read the analysis · 12 min

Company statements are taken from the primary release or filing and linked at the foot of each article. Share-price moves and analyst estimates are attributed to named reports — they are not company-published data. A first disclosure is rarely the complete one, so each piece states plainly what had not yet been released at the time of writing. Educational analysis only, not investment advice.

Earnings analysis Stock profiles Investing guides